{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:26:59Z","timestamp":1790735219884,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1105741"],"award-info":[{"award-number":["1105741"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1116930"],"award-info":[{"award-number":["1116930"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.brainres.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T02:30:57Z","timestamp":1533263457000},"page":"145902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["A sleeping giant: Suvorexant for the treatment of alcohol use disorder?"],"prefix":"10.1016","volume":"1731","author":[{"given":"Erin J.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2018.08.005_b0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.brainres.2018.08.005_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnins.2014.00033","article-title":"Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models","volume":"8","author":"Anderson","year":"2014","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13722-016-0056-7","article-title":"Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review","volume":"11","author":"Angarita","year":"2016","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"7","key":"10.1016\/j.brainres.2018.08.005_b0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"17","key":"10.1016\/j.brainres.2018.08.005_b0025","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1300\/J069v26n04_06","article-title":"Treatment options for sleep disturbances during alcohol recovery","volume":"26","author":"Arnedt","year":"2007","journal-title":"J. Addict. Dis."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.alcohol.2011.02.306","article-title":"Orexin A expression and promoter methylation in patients with alcohol dependence comparing acute and protracted withdrawal","volume":"45","author":"Bayerlein","year":"2011","journal-title":"Alcohol"},{"key":"10.1016\/j.brainres.2018.08.005_b0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnbeh.2013.00059","article-title":"The hypocretins and the reward function: what have we learned so far?","volume":"7","author":"Boutrel","year":"2013","journal-title":"Front. Behav. Neurosci"},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0045","first-page":"110","article-title":"Alcohol's effects on sleep in alcoholics","volume":"25","author":"Brower","year":"2001","journal-title":"Alcohol. Res. Health"},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1087-0792(03)90005-0","article-title":"Insomnia, alcoholism and relapse","volume":"7","author":"Brower","year":"2003","journal-title":"Sleep Med. Rev."},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.alcohol.2014.12.003","article-title":"Assessment and treatment of insomnia in adult patients with alcohol use disorders","volume":"49","author":"Brower","year":"2015","journal-title":"Alcohol"},{"issue":"8","key":"10.1016\/j.brainres.2018.08.005_b0060","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1530-0277.2008.00706.x","article-title":"A randomized double-blind pilot trial of gabapentin vs. placebo to treat alcohol dependence and comorbid insomnia","volume":"32","author":"Brower","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"9","key":"10.1016\/j.brainres.2018.08.005_b0065","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1017\/S1461145713000333","article-title":"Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats","volume":"16","author":"Brown","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.brainres.2018.08.005_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/adb.12251","article-title":"Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats","volume":"21","author":"Brown","year":"2016","journal-title":"Addict. Biol."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0075","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00213-018-4887-7","article-title":"New steps for treating alcohol use disorder","volume":"235","author":"Campbell","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0269881116629126","article-title":"Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: a case series","volume":"30","author":"Caputo","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.brainres.2018.08.005_b0085","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/acer.13217","article-title":"Alcohol dependence and its relationship with insomnia and other sleep disorders","volume":"40","author":"Chakravorty","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.brainres.2018.08.005_b0090","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/ijcp.12568","article-title":"Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic \u2013 What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"Citrome","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"2\u20133","key":"10.1016\/j.brainres.2018.08.005_b0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.drugalcdep.2006.06.008","article-title":"Alcohol treatment utilization: findings from the National Epidemiologic Survey on alcohol related conditions","volume":"86","author":"Cohen","year":"2007","journal-title":"Drug Alcohol. Depend."},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009731003597127","article-title":"The clock gene PER2 and sleep problems: association with alcohol consumption among Swedish adolescents","volume":"115","author":"Comasco","year":"2010","journal-title":"Ups. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.brainres.2018.08.005_b0105","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.ALC.0000141915.56236.40","article-title":"Association of sleep disturbance with chronicity and remission of alcohol dependence: data from a population-based prospective study","volume":"28","author":"Crum","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/acer.12006","article-title":"Alcohol and sleep I: effects on normal sleep","volume":"37","author":"Ebrahim","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"3","key":"10.1016\/j.brainres.2018.08.005_b0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1590\/S1516-44462009000300013","article-title":"Complaints of insomnia in hospitalized alcoholics","volume":"31","author":"Escobar-Cordoba","year":"2009","journal-title":"Rev. Bras Psiquiatr."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0120","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00213-018-4855-2","article-title":"From gene networks to drugs: systems pharmacology approaches for AUD","volume":"235","author":"Ferguson","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00004714-200212000-00009","article-title":"Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study","volume":"22","author":"Gastpar","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addict. Biol."},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol. Psychol."},{"issue":"23","key":"10.1016\/j.brainres.2018.08.005_b0140","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2012.04.012","article-title":"Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans","volume":"23","author":"Hoch","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2018.08.005_b0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnins.2013.00235","article-title":"Distinct effects of IPSU and suvorexant on mouse sleep architecture","volume":"7","author":"Hoyer","year":"2013","journal-title":"Front. Neurosci"},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.npep.2013.10.009","article-title":"Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?","volume":"47","author":"Hoyer","year":"2013","journal-title":"Neuropeptides"},{"issue":"5","key":"10.1016\/j.brainres.2018.08.005_b0160","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1161\/HYPERTENSIONAHA.115.07053","article-title":"Contribution of orexin to the neurogenic hypertension in BPH\/2J Mice","volume":"67","author":"Jackson","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.brainres.2018.08.005_b0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/7854_2016_56","article-title":"Role of the orexin\/hypocretin system in stress-related psychiatric disorders","volume":"33","author":"James","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"8","key":"10.1016\/j.brainres.2018.08.005_b0170","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/npp.2012.38","article-title":"Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia","volume":"37","author":"Johnson","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2018.08.005_b0175","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2011.03.045","article-title":"The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats","volume":"1391","author":"Jupp","year":"2011","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/ajp.157.1.151","article-title":"Gabapentin treatment for insomnia associated with alcohol dependence","volume":"157","author":"Karam-Hage","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2018.08.005_b9000","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1440-1819.2003.01161.x","article-title":"Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients","volume":"57","author":"Karam-Hage","year":"2003","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"Pt A","key":"10.1016\/j.brainres.2018.08.005_b0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2016.07.006","article-title":"Nucleus incertus Orexin2 receptors mediate alcohol seeking in rats","volume":"110","author":"Kastman","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2018.08.005_b0190","article-title":"Palatable food self-administration and reinstatement are not affected by dual orexin receptor antagonism","author":"Khoo","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.brainres.2018.08.005_b0195","doi-asserted-by":"crossref","first-page":"e0173967","DOI":"10.1371\/journal.pone.0173967","article-title":"The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking","volume":"12","author":"Khoo","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.brainres.2018.08.005_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136910","article-title":"Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"10","author":"Kishi","year":"2015","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nrd2828","article-title":"Development of pharmacotherapies for drug addiction: a Rosetta stone approach","volume":"8","author":"Koob","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.brainres.2018.08.005_b0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","article-title":"Drug abuse: hedonic homeostatic dysregulation","volume":"278","author":"Koob","year":"1997","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.brainres.2018.08.005_b0215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"19","key":"10.1016\/j.brainres.2018.08.005_b0220","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2174\/138161210791516431","article-title":"Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment","volume":"16","author":"Krampe","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"24","key":"10.1016\/j.brainres.2018.08.005_b0225","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"345","author":"Krystal","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0230","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.bjp.0706789","article-title":"The orexin system regulates alcohol-seeking in rats","volume":"148","author":"Lawrence","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.brainres.2018.08.005_b0235","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","article-title":"Acamprosate in alcohol dependence: how does it work?","volume":"90","author":"Littleton","year":"1995","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/WNF.0b013e3181cda242","article-title":"Treatment effects of gabapentin for primary insomnia","volume":"33","author":"Lo","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"22","key":"10.1016\/j.brainres.2018.08.005_b0245","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1001\/jama.2017.4760","article-title":"More Treatments on deck for alcohol use disorder","volume":"317","author":"Lyon","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0250","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5664\/jcsm.26741","article-title":"Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin","volume":"3","author":"Malcolm","year":"2007","journal-title":"J. Clin. Sleep. Med."},{"issue":"1\u20133","key":"10.1016\/j.brainres.2018.08.005_b0255","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician speciality","volume":"99","author":"Mark","year":"2009","journal-title":"Drug Alcohol. Depend."},{"issue":"1","key":"10.1016\/j.brainres.2018.08.005_b0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.brainres.2018.08.005_b0265","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jsat.2007.12.003","article-title":"Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual","volume":"35","author":"McGregor","year":"2008","journal-title":"J. Substance Abuse Treat."},{"issue":"26","key":"10.1016\/j.brainres.2018.08.005_b0270","first-page":"1","article-title":"Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use","volume":"8","author":"Merlo Pich","year":"2014","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.brainres.2018.08.005_b0275","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treat- ment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2018.08.005_b0280","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2017.09.029","article-title":"Insomnia treatment in the context of alcohol use disorder: a systematic review and meta-analysis","volume":"181","author":"Miller","year":"2017","journal-title":"Drug Alcohol. Depend."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0285","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00213-018-4871-2","article-title":"The hypocretin\/orexin system as a target for excessive motivation in alcohol use disorders","volume":"235","author":"Moorman","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"issue":"5","key":"10.1016\/j.brainres.2018.08.005_b0290","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.alcohol.2009.07.002","article-title":"Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol-preferring Sprague Dawley rats","volume":"43","author":"Moorman","year":"2009","journal-title":"Alcohol"},{"issue":"Pt A","key":"10.1016\/j.brainres.2018.08.005_b0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2016.10.018","article-title":"Orexin\/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats","volume":"1654","author":"Moorman","year":"2017","journal-title":"Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.brainres.2018.08.005_b0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0006-8993(94)90888-5","article-title":"Intraventricular administration of a FIV-envelope protein induces sleep architecture changes in rats","volume":"659","author":"Prospero-Garcia","year":"1994","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0305","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.psc.2015.07.008","article-title":"Sleep disturbance in substance use disorders","volume":"38","author":"Roehrs","year":"2015","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.brainres.2018.08.005_b0310","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"Rev(12)","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst."},{"key":"10.1016\/j.brainres.2018.08.005_b0315","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.brainres.2018.08.005_b0320","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-010-2127-x","article-title":"Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement","volume":"215","author":"Shoblock","year":"2010","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2018.08.005_b0330","series-title":"Addiction Research and Treatment: Converging trends: Proceedings of the First Annual Coatesville-Jefferson Conference on Addiction","first-page":"102-","article-title":"Sleep quality reported by drinking and non-drinking alcoholics","author":"Skoloda","year":"1979"},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0335","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2016.1146689","article-title":"Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential","volume":"17","author":"Soyka","year":"2016","journal-title":"Exp. Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.brainres.2018.08.005_b0340","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism \u2013 An update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Exp. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.brainres.2018.08.005_b0350","doi-asserted-by":"crossref","first-page":"e44726","DOI":"10.1371\/journal.pone.0044726","article-title":"The dual orexin\/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration","volume":"7","author":"Srinivasan","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.brainres.2018.08.005_b0355","first-page":"259","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","volume":"36","author":"Sun","year":"2013","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0360","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.alcohol.2014.07.019","article-title":"Alcohol disrupts sleep homeostasis","volume":"49","author":"Thakkar","year":"2015","journal-title":"Alcohol"},{"issue":"3","key":"10.1016\/j.brainres.2018.08.005_b0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0741-8329(92)90065-I","article-title":"Effects of ethanol injection to the preoptic area on sleep and temperature in rats","volume":"9","author":"Ticho","year":"1992","journal-title":"Alcohol"},{"issue":"3","key":"10.1016\/j.brainres.2018.08.005_b0370","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/ADT.0b013e31812e6a3c","article-title":"Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients","volume":"7","author":"Trevisan","year":"2008","journal-title":"Addict. Disord. Their Treat."},{"issue":"6","key":"10.1016\/j.brainres.2018.08.005_b0375","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.04.021","article-title":"Activation of Hypocretin-1\/Orexin-A Neurons projecting to the bed nucleus of the stria terminalis and paraventricular nucleus is critical for reinstatement of alcohol seeking by neuropeptide S","volume":"79","author":"Ubaldi","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.brainres.2018.08.005_b0380","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.yhbeh.2011.08.017","article-title":"Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence","volume":"60","author":"von der Goltz","year":"2011","journal-title":"Horm. Behav."},{"key":"10.1016\/j.brainres.2018.08.005_b0385","series-title":"Behavioral neuroscience of orexin\/hypocretin. Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2016_55","article-title":"The role of orexins\/\/hypocretins in alcohol use and abuse","author":"Walker","year":"2016"},{"key":"10.1016\/j.brainres.2018.08.005_b0390","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40495-016-0069-7","article-title":"Role of lateral hypothalamic orexin (hypocretin) neurons in alcohol use and abuse: recent advances","volume":"2","author":"Walker","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.brainres.2018.08.005_b0395","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnins.2014.00036","article-title":"Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls","volume":"8","author":"Yeoh","year":"2014","journal-title":"Front. Neurosci."},{"issue":"6740","key":"10.1016\/j.brainres.2018.08.005_b0400","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/22118","article-title":"The mPer2 gene encodes a functional component of the mammalian circadian clock","volume":"400","author":"Zheng","year":"1999","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.brainres.2018.08.005_b0405","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/alcalc\/agv129","article-title":"Orexin in patients with alcohol dependence treated for relapse prevention: a pilot study","volume":"51","author":"Ziolkowski","year":"2016","journal-title":"Alcohol. Alcohol."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318304190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899318304190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:19:24Z","timestamp":1777389564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899318304190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":82,"alternative-id":["S0006899318304190"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2018.08.005","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A sleeping giant: Suvorexant for the treatment of alcohol use disorder?","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"145902"}}